Cardiff Oncology is a clinical-stage biotechnology company developing novel cancer treatments centered on onvansertib, a highly selective oral PLK1 inhibitor that is designed to work in combination with standard-of-care therapies to treat various solid tumors and hematologic malignancies. The company's primary focus is treating patients with RAS-mutated metastatic colorectal cancer, which represents a significant market opportunity with limited existing treatment options, along with investigator-initiated trials in pancreatic cancer, small-cell lung cancer, triple-negative breast cancer, and chronic myelomonocytic leukemia. As a clinical-stage company with no current product revenues, Cardiff is funded through equity financing and strategic partnerships, including a collaboration with Pfizer on its lead clinical trial, and operates with the goal of advancing onvansertib through regulatory approval and eventual commercialization.